- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01732588
A Comparison of the Bioavailability of OZ439 When Delivered Directly to the Small Intestine, or Via the Oral Route
Three Way Randomised CrossOver Study in Healthy Subjects to Compare the Relative Bioavailability of Nanoparticulate OZ439 Delivered Via the Enterion™ Capsule to the Proximal Small Bowel With Orally Administered OZ439 as PIB Suspension and Orally Administered Nanoparticulate
The purpose of this study is to determine the bioavailability of nanoparticulate OZ439 delivered to the proximal small bowel (PSB) via the Enterion™ capsule relative to oral OZ439 suspension (current "powder in bottle" [PIB]) and oral nanoparticulate OZ439.
The study will also characterise the plasma concentration time profile of OZ439 when delivered via Enterion capsule to the PSB in comparison with OZ439 PIB formulation delivered orally and nanoparticulate OZ439 delivered orally Safety and tolerability of OZ439 formulations will be determined following delivery to the PSB and administered orally
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Nottingham, United Kingdom, NG11 6JS
- Quotient Clinical
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy males, or females of non-childbearing potential ie surgically sterilised or post-menopausal
- Age 18 to 55 years
- Body mass index of 18 to 30 kg/m2 inclusive
- Total body weight >50 kg
- Healthy as determined by pre-study medical history, physical examination (including body temperature) and 12-lead ECG
- Must have haematology, clinical chemistry and urinalysis results at screening that are within the reference range or ncs
- Must agree to use an adequate method of contraception
- Must demonstrate their ability to swallow an empty size 000 capsule
- Must be willing and able to communicate and participate in the whole study
- Must provide written informed consent
Exclusion Criteria:
- Evidence or history of clinically significant oncological, pulmonary, chronic respiratory, hepatic, cardiovascular, haematological, metabolic, neurological, immunological, nephrological, endocrine or psychiatric disease, or current infection
- Clinically relevant abnormalities in the ECG (12 standard leads) and/or QTcF >450 ms (males) or >470 ms (females)
- Evidence or history of clinically significant GI disease or surgery (excluding appendectomy or cholecystectomy)
- Any condition that could possibly affect drug absorption, eg gastrectomy or diarrhoea
- History of post-antibiotic colitis
- History of any drug or alcohol abuse in the past 2 years prior to screening
- Subjects who have a breath carbon monoxide reading of greater than 10 ppm at screening. Subjects who are tobacco users (including smokers and users of snuff, chewing tobacco and other nicotine or nicotine-containing products) must have stopped use within 90 days before screening
- Receipt of an investigational drug or participation in another clinical research study within the previous 3 months
- Subjects who are study site employees, or immediate family members of a study site or sponsor employee
- Subjects who have previously been enrolled in this study
- Use of any prescription or non-prescription medications, vitamins, herbal supplements or dietary supplements within 14 days prior to the first dose
- Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab)or human immunodeficiency virus (HIV-1 or HIV-2 antibody) results
- Positive urine drug screen result
- History of intolerance or hypersensitivity to artemisinins
- Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
- Presence or history of allergy requiring treatment; hayfever is allowed unless it is active
- Donation or loss of >400 mL of blood within the previous 3 months
- Haemoglobin result below the lower limit of the reference range
- Regular alcohol consumption in males >21 units per week and females >14 units per week
- Subjects who do not have suitable veins
- Acute diarrhoea or constipation in the 7 days before the predicted first study day.
- Presence of non-removable metal objects in the abdomen
- Radiation exposure exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years
- Failure to satisfy the investigator of fitness to participate for any other reason
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Regimen A - 120mg OZ439 PIB
120mg single dose of OZ439 as powder in bottle (PIB) formulation
|
120mg dose (as free base) of OZ439 as a solution made up from powder in bottle (PIB)
Other Names:
|
Experimental: Regimen B - 120 mg OZ439 IR caplet
120 mg single dose of OZ439 immediate release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
|
120 mg (as free base) of OZ439 immediate-release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
Other Names:
|
Experimental: Regimen C - 120 mg OZ439 caplet via Enterion capsule
120 mg single dose of OZ439 caplet formulation containing nanoparticulate, administered orally via the Enterion capsule and delivered to the proximal small bowel
|
120 mg OZ439 (as free base) in an immediate release (IR) caplet formulation containing nanoparticulate,administered orally via the Enterion capsule and delivered directly to the proximal small bowel (PSB)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OZ439 AUC0-∞
Time Frame: pre dose, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post dose
|
Area under the plasma concentration-time curve from zero to infinity (AUC0-∞)
|
pre dose, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post dose
|
OZ439 Cmax
Time Frame: pre dose, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post dose
|
The maximum observed plasma drug concentrations (Cmax)
|
pre dose, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OZ439 Tmax
Time Frame: pre dose, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post dose
|
Time of maximum observed plasma drug concentrations (Tmax)
|
pre dose, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post dose
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Fiona Macintyre, PhD, Medicines for Malaria Venture
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MMV_OZ439_12_003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on OZ439 120mg PIB
-
Medicines for Malaria VentureSyneos Health; Nucleus Network LtdCompletedHealthy VolunteersAustralia
-
Medicines for Malaria VentureRichmond Pharmacology LimitedCompleted
-
Medicines for Malaria VentureCompletedHealthy Volunteers | Malaria Falciparum | Malaria VivaxUnited States
-
Medicines for Malaria VentureQuotient ClinicalCompleted
-
José A. LuchsingerNational Institute on Aging (NIA); Wake Forest UniversityEnrolling by invitationVascular Diseases | Atherosclerosis | Cognitive Impairment | Alzheimer DiseaseUnited States
-
New Cancer Cure-Bio Co.,Ltd.RecruitingAdvanced Solid TumorsKorea, Republic of
-
University of Southern CaliforniaNational Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Alzheimer's Clinical Trials ConsortiumRecruitingDementia | Alzheimer Disease | Down SyndromeUnited States, Spain, United Kingdom
-
Boehringer IngelheimCompleted
-
Oriental Neurosurgery Evidence-Based-Study TeamUnknownParkinson DiseaseChina
-
Washington University School of MedicineNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes... and other collaboratorsRecruiting